Disease-modifying treatments for Alzheimer disease (AD) have focused mainly on reducing
levels of amyloid-β (Aβ) in the brain. Some compounds have achieved this goal, but none …

Alzheimer's disease (AD) is recognized as a major health hazard that mostly affects people
older than 60 years. AD is one of the biggest medical, economic, and social concerns to …

Introduction Alzheimer's disease (AD) has few available treatments, and there is a high rate
of failure in AD drug development programs. Study of the AD drug development pipeline can …

Few diagnoses in modern medicine evoke more apprehension in patients and their families
than Alzheimer disease (AD). Defined as a clinical and pathological entity a century ago, the …

The number of people with Alzheimer's disease has never been greater and is set to
increase substantially in the decades ahead as the proportion of the population aged 65 …

Introduction Alzheimer's disease (AD) is a growing public health concern affecting millions of
patients worldwide and costing billions of dollars annually. We review the pipeline of drugs …

Alzheimer's disease (AD) is the most common cause of cognitive impairment in older
patients and is expected to increase greatly in prevalence in the next future. It is …

Alzheimer's disease (AD) and other dementias represent a significant and increasing clinical
challenge. This review highlights current treatment options for AD and the main focusses of …

Alzheimer disease (AD) drug development has a high failure rate. Drug development
decision making can be improved based on lessons learned from past trials. Improved …

Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …